Evidence map›Paper›PMID 38006028›Full record

ArticleVaccines2023

Impact of Vaccination on the Course and Outcome of COVID-19 in Patients with Multimorbidity.

Kirill Lomonosov, Alyona Lomonosova, Alla Mindlina, Roman Polibin, Maksim Antipov, Gleb Grimm

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kirill LomonosovFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119991, Russia.
Alyona LomonosovaFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119991, Russia.
Alla MindlinaFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119991, Russia.
Roman PolibinFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119991, Russia.ORCID 0000-0003-4146-4787
Maksim AntipovFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119991, Russia.ORCID 0000-0001-7570-4035
Gleb GrimmFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119991, Russia.
Sechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccination is the most cost-effective method of preventing COVID-19; however, data on its effect on patients with multimorbidity is limited. The aim was to evaluate the effect of vaccination against new coronavirus infection (NCI) in patients with multimorbid pathology in hospital treatment on the outcome of COVID-19 disease. An analysis was carried out of 1832 records of patients in one of the COVID-19 hospitals in Moscow for 2020-2022. Statistical analysis was carried out using the StatTech v. 3.1.3 software, and the binary logistic regression (BLR) method was used to obtain prognostic models. The median age of patients was 69 years, and 76% of them had received two vaccine doses. To assess the outcome of the disease, two prognostic models were obtained depending on the presence of a multimorbidity in patients: cardiovascular pathology and/or atherosclerosis and/or type 2 diabetes mellitus (Model 1) or atherosclerosis and/or type 2 diabetes mellitus and/or encephalopathy (Model 2), against the background of the presence or absence of vaccination against NCI. When assessing the outcome of NCI in Model 1, the odds of death decreased by 3.228 times with two doses of Sputnik V in patients with multimorbidity. According to Model 2, for patients with multimorbidity, the chances of death decreased by 3.281 times with two doses of Sputnik V. The presence of two doses of Sputnik V increased the likelihood of recovery in patients with multimorbidity by more than three times.

Indexed as

COVID-19epidemiologymultimorbidityvaccination

Identifiers

PMID38006028
PMCPMC10674179
OpenAlexW4388465198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.